{"nctId":"NCT00157157","briefTitle":"Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients","startDateStruct":{"date":"2004-04-01","type":"ACTUAL"},"conditions":["Hemophilia A"],"count":66,"armGroups":[{"label":"Single Arm - All Participants","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)"]}],"interventions":[{"name":"Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level \\<= 2% of normal, as documented at screening\n* The subject is \\< 6 years of age\n* The subject's legally authorized representative has provided written informed consent\n\nExclusion Criteria:\n\n* The subject has a history of exposure to factor VIII other than rAHF PFM or more than 3 infusions of commercially available rAHF PFM (i.e., ADVATE) within 28 days prior to screening, as determined by the subject's medical history. Any infusion of factor VIII replacement products prior to the 28-day period excludes the subject from participation\n* The subject has received more than 3 infusions of rAHF PFM (commercially available and/or study product) between screening and prior to the initial recovery infusion\n* The subject has a detectable inhibitor to factor VIII, as measured in the screening sample by the Nijmegen assay in the central laboratory\n* The subject has a history of inhibitor to factor VIII at any time prior to screening\n* The subject has a known hypersensitivity to rAHF PFM\n* The subject has any 1 of the following laboratory abnormalities at the time of screening:\n\n  1. Platelet count \\< 100,000/mm\\^3\n  2. Hemoglobin concentration \\< 10 g/dL (100 g/L)\n  3. Serum creatinine \\> 1.5 times the upper limit of normal (ULN) for age\n  4. Total bilirubin \\> 2 times the ULN for age\n* The subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative platelet defect or von Willebrand's disease)\n* The subject is known to be seropositive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV), as determined by the subject's medical history\n* At the time of enrollment, the subject has a clinically significant chronic disease other than hemophilia A\n* The subject is currently participating in another investigational drug study, or has participated in any clinical study involving an investigational drug within 120 days of the screening visit\n* The subject (or the subject's legally authorized representative) is identified by the investigator as being unable or unwilling to cooperate with study procedures\n* The subject has received any blood product, including packed red blood cells (RBC), platelets, plasma, or cryoprecipitate","healthyVolunteers":false,"sex":"ALL","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Factor VIII Inhibitor Development","description":"Percentage of treated participants who developed factor VIII inhibitors","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Bleeding Episodes Treated With 1 to ≥4 Infusions","description":"The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"356","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Hemostasis for Treatment of Bleeding Episodes","description":"Number of rAHF-PFM-treated bleeding episodes with treater assessment of hemostasis (4-point ordinal scale): Excellent: Full pain relief \\& bleeding cessation within \\~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis; Good: Definite pain relief and/or improvement in bleeding within \\~8 hrs after infusion. Possibly requires \\>1 infusion for complete resolution; Fair: Probable or slight relief of pain \\& slight improvement in bleeding within \\~8 hrs after infusion. Requires \\>1 infusion for complete resolution; or None: No improvement or condition worsens.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Bleeding Episodes","description":"Number of bleeding episodes per subject annualized over 1 year for all etiologies","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Weekly rAHF-PFM Utilization","description":"Weight-Adjusted Weekly Dose for Prophylaxis, On-Demand Treatment, and Perioperative Management. rAHF-PFM dose determined by the investigator (ie: standard regimen \\[25-50 IU/kg body weight, 3-4 times per week\\]; modified prophylactic regimen \\[dose and frequency selected by investigator\\] or on-demand treatment \\[dose selected by investigator\\]). Dosing to treat BEs was at investigator's discretion and in accordance with institution's standard of care. rAHF-PFM was administered I.V. via bolus infusion, except for perioperative management when it was given either by continuous or bolus infusion.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"606.4","spread":null}]}]}]},{"type":"SECONDARY","title":"In Vivo Incremental Recovery","description":"Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":null},{"groupId":"OG001","value":"1.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Intra-operative Hemostasis","description":"Number of surgical procedures managed with rAHF-PFM and with surgeon's assessment of hemostasis based on a 4-point ordinal scale: Excellent: ≤ average predicted blood loss for matched procedures in healthy individuals Good: \\> average predicted blood loss, but ≤ maximal predicted blood loss for matched procedures in healthy individuals Fair: \\> maximal predicted blood loss for matched procedures in healthy individuals, and hemostasis was achieved None: uncontrolled hemostasis with proper dosing, necessitating a change in treatment regimen","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Postoperative Hemostasis","description":"Number of surgical procedures managed with rAHF-PFM and with investigator's assessment of hemostasis based on a 4-point ordinal scale: Excellent: hemostasis was as good as or better than other licensed factor VIII products for matched procedure Good: hemostasis was probably as good as other licensed factor VIII products for matched procedure Fair: hemostasis was clearly \\< optimal for matched procedure, without need to change regimen None: bleeding from inadequate response with proper dosing, necessitating a change in regimen","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Blood Loss During Surgical Procedures","description":"Percentage of actual intraoperative blood loss compared to preoperatively predicted average and maximal blood loss in hemostatically normal matched individuals (from institutional blood bank records)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events Deemed Related to Treatment","description":"Percentage of participants who reported AEs deemed related to treatment with rAHF-PFM","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Development of Antibodies to Heterologous Proteins","description":"Percentage of treated participants who developed antibodies to heterologous proteins (ie, Chinese Hamster Ovary Cell Protein, Murine IgG, or Recombinant Human VWF)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"POST_HOC","title":"Factor VIII Inhibitor Risk Factor: Genetic Risk Factor- Family History of Inhibitors","description":"Number of treated participants who developed an inhibitor","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"POST_HOC","title":"Factor VIII Inhibitor Risk Factor: Race","description":"Number of treated participants who developed an inhibitor","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"POST_HOC","title":"Factor VIII Inhibitor Risk Factor: Number of Participants With Intensive Treatment and High Dose (≤20 Exposure Days (EDs))","description":"Immunogenicity Analysis Set- Participants with 5 consecutive study days of a mean infusion dose of FVIII \\>50 IU/kg within ≤20 EDs who developed an inhibitor","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":55},"commonTop":["Pyrexia","Nasopharyngitis","Cough","Rhinorrhoea","Diarrhea"]}}}